Edaravone Injection

DRUG4 trials

Sponsors

Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Yoko Biomedical Co., Ltd.

Conditions

Acute Ischemic StrokeDrug-drug Interaction

Phase 1

Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection

CompletedNCT04218513

Nanjing Yoko Biomedical Co., Ltd.Drug-drug Interaction

Start: 2019-05-10End: 2019-05-31Updated: 2021-03-22

Phase 2

Compound Edaravone Injection for Acute Ischemic Stroke

CompletedNCT01929096

Jiangsu Simcere Pharmaceutical Co., Ltd.Acute Ischemic Stroke

Start: 2013-08-31End: 2015-02-28Updated: 2015-07-03

Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

SuspendedNCT04984577

Nanjing Yoko Biomedical Co., Ltd.Acute Ischemic Stroke

Start: 2021-11-15End: 2026-12-31Target: 240Updated: 2024-02-20

Phase 3

Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

CompletedNCT02430350

Jiangsu Simcere Pharmaceutical Co., Ltd.Acute Ischemic Stroke

Start: 2015-05-31End: 2016-12-31Updated: 2017-01-16

Related Papers

Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke

Stroke2021-02-16211 citations

Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial

Stroke and Vascular Neurology2019-04-2297 citations